The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor

被引：0
|
作者：
Nenad Sarapa
Margaret R. Britto
Michelle B. Mainka
Kourosh Parivar
机构：
[1] Clinical PK/PD,Pfizer Global Research & Development
[2] Clinical Pharmacology,Quintiles Inc.
[3] Statistics and Programming,Pfizer Global Research & Development
来源：
European Journal of Clinical Pharmacology | 2005年 / 61卷
关键词：
Valdecoxib; Pharmacokinetics; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 256
页数：9
相关论文
共 50 条
  • [21] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [22] Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment
    Wang, Jing
    Wang, Xiaodong
    Zhang, Zhi-Yi
    Arora, Sujata
    Lu, Sharon
    Kansra, Vikram
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05): : 686 - 693
  • [23] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Michael A. Tortorici
    Melvin Toh
    S. V. Rahavendran
    Robert R. LaBadie
    Christine W. Alvey
    Thomas Marbury
    Ernesto Fuentes
    Matthew Green
    Grace Ni
    Brian Hee
    Yazdi K. Pithavala
    Investigational New Drugs, 2011, 29 : 1370 - 1380
  • [24] Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Liu, Yani
    Zhang, Rui
    Li, Zhongfang
    Zhou, Jiali
    Yang, Tingyu
    Yang, Chunxiao
    Huang, Xixi
    Zhang, Yu
    Shi, Shaojun
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Yani Liu
    Rui Zhang
    Zhongfang Li
    Jiali Zhou
    Tingyu Yang
    Chunxiao Yang
    Xixi Huang
    Yu Zhang
    Shaojun Shi
    Scientific Reports, 9
  • [26] Rofecoxib: A selective COX-2 inhibitor
    不详
    Drugs & Therapy Perspectives, 2000, 15 (2) : 1 - 5
  • [27] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [28] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [29] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    Drugs in R&D, 2021, 21 : 375 - 384
  • [30] Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
    Desai, Amit
    Schmitt-Hoffmann, Anne-Hortense
    Mujais, Salim
    Townsend, Robert
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3025 - 3031
12345